Clinical Outcomes of Breast Cancer in Carriers of BRCA1 and BRCA2 Mutations

• Published in: The New England journal of medicine Vol. 357; no. 2; pp. 115 - 123
• Main Authors: Rennert, Hedy S, Rennert, Gad, Bisland-Naggan, Shantih, Barnett-Griness, Ofra, Bar-Joseph, Naomi, Zhang, Shiyu, Narod, Steven A
• Format: Journal Article
• Language: English
• Published: Boston, MA Massachusetts Medical Society 12.07.2007
• Subjects: Adult; Age of Onset; Analysis of Variance; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - ethnology; Breast Neoplasms - genetics; Breast Neoplasms - mortality; Clinical outcomes; Female; Genealogy; General aspects; Genes, BRCA1; Genes, BRCA2; Gynecology. Andrology. Obstetrics; Heterozygote; Humans; Israel - epidemiology; Jewish people; Jews - genetics; Kaplan-Meier Estimate; Mammary gland diseases; Medical sciences; Middle Aged; Mutation; Prevalence; Prognosis; Proportional Hazards Models; Registries; Retrospective Studies; Risk Factors; Survival Rate; Tumors; Womens health; Israel; Prognosis; Breast cancer; Malignant tumor; Medicine; Mammary gland diseases; BRCA2 gene; Evolution; Genetics; Mammary gland; Mutation; Carrier; BRCA1 gene; Tumor suppressor gene
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa070608

In a retrospective, registry-based study of breast cancer in Israel, 10% of Ashkenazi women with breast cancer had a mutation in either BRCA1 or BRCA2 . Breast-cancer–specific survival was similar among carriers and noncarriers of these mutations. In a study of breast cancer in Israel, 10% of Ashkenazi women with breast cancer had a mutation in either BRCA1 or BRCA2 . Breast-cancer–specific survival was similar among carriers and noncarriers of these mutations. Breast cancer is the leading cause of all deaths from cancer among Israeli women. 1 Approximately 3800 women receive the diagnosis of breast cancer annually in this population; in 28% of these women, breast cancer is diagnosed before the age of 50 years. 1 To some extent, the high proportion of cases in young women reflects the high prevalence of hereditary breast cancers in Jewish women. Approximately 60% of Israeli Jews are Ashkenazi, and others are Sephardi, Iraqi, or of mixed ancestry; there are also Muslim, Christian, and Druze residents. Two mutations in BRCA1 (185delAG and 5382insC) and one in BRCA2 (6174delT) . . .